During the last session, Cardiff Oncology Inc (NASDAQ:CRDF)’s traded shares were 0.52 million, with the beta value of the company hitting 2.03. At the end of the trading day, the stock’s price was $4.07, reflecting an intraday gain of 2.01% or $0.08. The 52-week high for the CRDF share is $6.42, that puts it down -57.74 from that peak though still a striking 76.9% gain since the share price plummeted to a 52-week low of $0.94. The company’s market capitalization is $181.85M, and the average trade volume was 1.84 million shares over the past three months.
Cardiff Oncology Inc (NASDAQ:CRDF) trade information
Cardiff Oncology Inc (CRDF) registered a 2.01% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 2.01% in intraday trading to $4.07, hitting a weekly high. The stock’s 5-day price performance is -6.44%, and it has moved by -29.22% in 30 days. Based on these gigs, the overall price performance for the year is 164.29%.
Cardiff Oncology Inc (CRDF) estimates and forecasts
Statistics show that Cardiff Oncology Inc has underperformed its competitors in share price, compared to the industry in which it operates. Cardiff Oncology Inc (CRDF) shares have gone up 299.02% during the last six months, with a year-to-date growth rate less than the industry average at -5.38% against 12.90. In the rating firms’ projections, revenue will decrease -50.80% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 50k as predicted by 4 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 60k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 83k and 108k respectively. In this case, analysts expect current quarter sales to shrink by -39.80% and then drop by -44.40% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 35.42%. While earnings are projected to return -4.78% in 2024.
CRDF Dividends
Cardiff Oncology Inc is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
